8月4日 - ** 生物技术公司Lisata Therapeutics（LSTA.O）的股价在盘前交易中下跌1.9%，至1.02美元
** LSTA 表示，在与 (link) 旗下 Kuva Labs 及其子公司 Kuva Acquisition Corp 的拟议合并终止后，该公司已对上述两家公司提起诉讼，并裁减了约 72% 的全职员工以削减成本
** 这家抗癌药物开发商正代表股东寻求赔偿，并要求Kuva根据合并协议支付200万美元的终止赔偿金
** 此次裁员包括解雇研发执行副总裁兼首席医学官
** 称其董事会正在考虑多种方案，包括出售、合并、出售公司资产或清算业务；未透露做出决定的时间表
** 截至上一交易日收盘，LSTA今年以来累计下跌44%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.